Eddingpharm To Market Afib Drug In China For Cardiome Pharma Corp.

Eddingpharm, a company that in-licenses drugs for China marketing, secured greater China rights to Brinavess™ from Cardiome Pharma of Canada. Brinavess is a treatment for recent onset atrial fibrillation. Eddingpharm paid $1 million upfront and will make up to $3 million in regulatory milestones. It will also be responsible for meeting China regulatory requirements, including clinical trials, and agreed to undisclosed sales targets for Brinavess.

Help employers find you! Check out all the jobs and post your resume.